FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with application of mutein of human interleukin-2(mutein hIL-2), which has amino acid substitution of asparagine in position 88 for arginine or glycine or for isoleucine and/or substitution of aspartic acid in position 20 for histidine or isoleucine, or for tyrosine and/or substitution of glutamine in position 126 for leucine to prepare medication, intended for treatment and/or prevention of autoimmune disease and for formation of regulatory T-cells in living organism.
EFFECT: group of inventions provides good tolerability and low toxicity of medication.
12 cl, 10 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE AGONISTS AND ANTAGONISTS OF IL-2 | 1999 |
|
RU2235729C2 |
| DESIGNED IL-2-FC FUSION PROTEINS | 2018 |
|
RU2812283C2 |
| NEW SUBPOPULATION OF TREG CD8CD45RC CELLS AND ITS APPLICATIONS | 2016 |
|
RU2766691C2 |
| PROMOTING AGENT OF PROLIFERATION OF REGULATORY T-LYMPHOCYTE, AND THEIR PROMOTION METHOD | 2012 |
|
RU2499043C1 |
| METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| METHODS FOR IDENTIFICATION, SELECTION, ENRICHMENT AND DEPLETION OF Tr1 CELLS POPULATIONS, Tr1 CELLS POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR THERAPY EFFECT MONITORING | 2011 |
|
RU2627445C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
| METHOD FOR OBTAINING AUTOLOGOUS REGULATORY T-LYMPHOCYTES BY EX VIVO CULTIVATION IN PRESENCE OF HUMAN CHORIONIC GONADOTROPIN | 2022 |
|
RU2791738C1 |
| MONOCYTIC SELF-SPECIFIC CELLS, STIMULATING AUTOTOLERANCE, AND THEIR USE IN PHARMACEUTIAL PREPARATIONS | 2004 |
|
RU2346041C2 |
